Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Change in Account Payables (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Change in Account Payables data on record, last reported at $18000.0 in Q3 2025.

  • For Q3 2025, Change in Account Payables rose 12.5% year-over-year to $18000.0; the TTM value through Sep 2025 reached $176000.0, up 220.55%, while the annual FY2024 figure was -$445000.0, 74.89% up from the prior year.
  • Change in Account Payables reached $18000.0 in Q3 2025 per CYCN's latest filing, up from -$21000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.3 million in Q4 2022 and bottomed at -$2.1 million in Q2 2023.
  • Average Change in Account Payables over 5 years is -$74764.7, with a median of $16000.0 recorded in 2024.
  • Peak YoY movement for Change in Account Payables: surged 1379.63% in 2022, then tumbled 931.05% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at -$232000.0 in 2021, then skyrocketed by 671.12% to $1.3 million in 2022, then tumbled by 70.94% to $385000.0 in 2023, then plummeted by 77.66% to $86000.0 in 2024, then plummeted by 79.07% to $18000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $18000.0 in Q3 2025, -$21000.0 in Q2 2025, and $93000.0 in Q1 2025.